Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11976380 | 1.00 | CYP3A4 (0.35) | CYP3A4TSHRALDH1A1LMNAPOLB | |
| SCHEMBL15483710 | 1.00 | CYP3A4 (0.35) | CYP3A4TSHRALDH1A1LMNAPOLB | |
| SCHEMBL8434138 | 1.00 | CYP3A4 (0.35) | CYP3A4TSHRALDH1A1LMNAPOLB | |
| SCHEMBL27870598 | 0.82 | — | — | |
| SCHEMBL16843474 | 0.82 | CYP3A4 (0.33) | CYP3A4TSHRALDH1A1LMNAPOLB | |
| SCHEMBL10941440 | 0.82 | CYP3A4 (0.33) | CYP3A4TSHRALDH1A1LMNAPOLB | |
| SCHEMBL9611225 | 0.79 | ALDH1A1 (0.36) | ALDH1A1LMNAPOLBNPSR1ATM | |
| SCHEMBL12164497 | 0.79 | ALDH1A1 (0.36) | ALDH1A1LMNAPOLBNPSR1ATM | |
| SCHEMBL3429780 | 0.79 | ALDH1A1 (0.36) | ALDH1A1LMNAPOLBNPSR1ATM | |
| SCHEMBL11976293 | 0.79 | ALDH1A1 (0.36) | ALDH1A1LMNAPOLBNPSR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700552-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-7553881-B2 | Dental materials based on radically polymerizable macromers with antimicrobial effect | IVOCLAR VIVADENT AG (LI) | 2009-06-30 | — | — | US | disclosed |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-1910347-A2 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | MEDIVIR AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| US-20070254979-A1 | Dental materials based on radically polymerizable macromers with antimicrobial effect | IVOCLAR VIVADENT AG (LI) | 2007-11-01 | — | — | US | disclosed |
| WO-2007017144-A2 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | MEDIVIR AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | CTRC, NOX3, HAVCR2 | CYP3A4 1186/4885TSHR 1326/4885ALDH1A1 2532/4885 |
| US-20070254979-A1 | Dental materials based on radically polymerizable macromers with antimicrobial effect | MSR1, PAM, C1R | CYP3A4 2207/4885TSHR 1235/4885ALDH1A1 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.